| pubmed-article:12150448 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C1817976 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C1306673 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C1705180 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C0086035 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C0439662 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C0205421 | lld:lifeskim |
| pubmed-article:12150448 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:12150448 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12150448 | pubmed:dateCreated | 2002-8-1 | lld:pubmed |
| pubmed-article:12150448 | pubmed:abstractText | The development of delayed-type hypersensitivity (DTH) response to recall antigens has long been utilized as a measure of immune competence. It is assumed that because patients with advanced stage cancers exhibit multiple immune system defects they may not be responsive to immunization. We pre-selected patients with advanced HER-2/neu (HER2) overexpressing breast and ovarian cancers for enrolment into a phase I trial designed to evaluate the immunogenicity of a HER2 peptide vaccine based on the patient's immune competence as assessed by DTH skin testing to common recall antigens (Multitest CMI, Institut Merieux, Lyon, France). At the time of a positive DTH response to tetanus toxoid (tt) peripheral blood was obtained to measure T cell responses to tt. Of 53 patients evaluated, 38 (72%) were not anergic. Among the 15 (28%) who were, seven patients with advanced stage breast cancer were re-tested a median of 26 days (range 12-150 days) after receiving a tt bopster vaccination. Five of the seven had positive DTH responses when re-challenged with tt and six had peripheral blood tetanus specific T cell response with stimulation index >2.0. Thus, the majority of patients studied with advanced stage breast or ovarian cancer were able to mount a DTH response to common recall antigens. Moreover, a negative response by DTH testing to a battery of common recall antigens was not a reflection of the breast cancer patient's ability to mount a cell-mediated immune response to a vaccinated antigen, tt. | lld:pubmed |
| pubmed-article:12150448 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12150448 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12150448 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12150448 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12150448 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12150448 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12150448 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12150448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12150448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12150448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12150448 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12150448 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12150448 | pubmed:issn | 0167-6806 | lld:pubmed |
| pubmed-article:12150448 | pubmed:author | pubmed-author:SchiffmanKath... | lld:pubmed |
| pubmed-article:12150448 | pubmed:author | pubmed-author:DisisMary LML | lld:pubmed |
| pubmed-article:12150448 | pubmed:author | pubmed-author:RinnKristineK | lld:pubmed |
| pubmed-article:12150448 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12150448 | pubmed:volume | 74 | lld:pubmed |
| pubmed-article:12150448 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12150448 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12150448 | pubmed:pagination | 17-23 | lld:pubmed |
| pubmed-article:12150448 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:meshHeading | pubmed-meshheading:12150448... | lld:pubmed |
| pubmed-article:12150448 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12150448 | pubmed:articleTitle | Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients. | lld:pubmed |
| pubmed-article:12150448 | pubmed:affiliation | Tumor Vaccine Group, University of Washington, Seattle 98195-6527, USA. kschiff@u.washington.edu | lld:pubmed |
| pubmed-article:12150448 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12150448 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12150448 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
